Previous 10 | Next 10 |
2024-02-05 11:04:02 ET Major earnings expected before the bell on Tuesday include: BP ( BP ) Cummins ( CMI ) DuPont de Nemours ( DD ) Eli Lilly and Co. ( LLY ) Spotify Technology ( SPOT ) Read the full article on Seeking Alpha For furt...
2024-02-05 11:00:36 ET More on Deciphera Pharmaceuticals Deciphera: Upside Potential For The Patient Investor Deciphera Pharmaceuticals: Moving The Needle Where It Counts Deciphera forges exclusive distribution deal with Genesis Pharma Seeking Alpha’s ...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tu...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Gu...
– Median Overall Survival for QINLOCK ® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population – – Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer Patients with Grade 3/4 Treatment-Emergent Advers...
2024-01-09 04:37:11 ET Summary Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's pivotal phase 3 study of vimseltinib in TGCT ha...
– Preliminary Unaudited Fourth Quarter 2023 QINLOCK ® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug Application (NDA) in the Second Quarter of 2024 and ...
2024-01-07 23:48:01 ET Summary Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor vimseltinib, with promising response rates in phase...
– Median Progression-Free Survival for QINLOCK ® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib – – Median Overall Survival for QINLOCK was Not Estimable Versus 1...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to th...